| scholarly article | Q13442814 |
| P50 | author | Suresh K Mittal | Q104783680 |
| P2093 | author name string | Shruti Shukla | |
| Dinesh S Bangari | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 960-966 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture | |
| P478 | volume | 327 |
| Q38721445 | 155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication |
| Q56901675 | A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose |
| Q33778607 | A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model |
| Q33565630 | Adenoviral vector immunity: its implications and circumvention strategies |
| Q37409025 | Adenoviral vector-based strategies for cancer therapy |
| Q33994011 | Adenovirus receptors and their implications in gene delivery |
| Q38283820 | Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. |
| Q37508260 | Adenovirus: the first effective in vivo gene delivery vector |
| Q37945220 | An update on canine adenovirus type 2 and its vectors |
| Q30229074 | Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus |
| Q37346346 | Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry |
| Q40424773 | Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. |
| Q33848987 | Bovine adenovirus type 3 virions cannot be rescued in vivo after full-length viral genome transfection in the absence of detectable polypeptide IX. |
| Q38286656 | Bovine adenovirus-3 as a vaccine delivery vehicle. |
| Q34643252 | Chapter two--Adenovirus strategies for tissue-specific targeting |
| Q26995655 | Circumventing antivector immunity: potential use of nonhuman adenoviral vectors |
| Q37309252 | Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. |
| Q34585554 | Current strategies and future directions for eluding adenoviral vector immunity |
| Q26782083 | Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs |
| Q30352927 | Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. |
| Q36317264 | Development of nonhuman adenoviruses as vaccine vectors |
| Q39641583 | Efficient replication and generation of recombinant bovine adenovirus‐3 in nonbovine cotton rat lung cells expressing I‐SceI endonuclease |
| Q37137464 | Emerging cancer vaccines: the promise of genetic vectors. |
| Q37567831 | Engineered adenovirus serotypes for overcoming anti-vector immunity |
| Q39624050 | Enhanced transduction of CAR-negative cells by protein IX-gene deleted adenovirus 5 vectors. |
| Q33848838 | Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. |
| Q34153735 | Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model |
| Q40155024 | Evaluation of promoters for driving efficient transgene expression in neonatal porcine islets. |
| Q34301004 | Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice |
| Q21134724 | Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine |
| Q36976598 | Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41 |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q35393576 | Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines |
| Q38284700 | Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?. |
| Q35672866 | Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer |
| Q42259707 | Structure-based identification of a major neutralizing site in an adenovirus hexon |
| Q41452234 | The use of bacterial minicells to transfer plasmid DNA to eukaryotic cells |
Search more.